Business Context and Reporting Period
Company: Lineage Cell Therapeutics, Inc. (LCTX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2025
Event: Item 8.01 Other Events – Block transaction under an at-the-market offering program.
Key Financial Metrics
This filing reports a specific capital raising event rather than periodic financial performance metrics (e.g., revenue, profit, or cash flow from operations).
| Metric | Value |
|---|---|
| Shares Sold | 12,000,000 |
| Purchase Price per Share | $1.75 |
| Gross Proceeds | $21 million |
| Buyer | Janus Henderson Investors |
Note: The filing does not provide data on net proceeds after fees, current debt levels, or liquidity ratios.
Material Changes
The filing discloses a material change in the company's capital structure through the issuance of 12 million common shares. This transaction increases the total number of outstanding shares and provides immediate gross cash inflow of $21 million.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the transaction itself. No unusual items or contingencies are described in this report.
Investor Verification Checklist
- Verify the exact amount of fees and expenses deducted from the $21 million gross proceeds to determine net cash received.
- Confirm the updated total number of outstanding shares post-transaction to assess dilution impact.
- Review the remaining capacity under the at-the-market offering program.
- Check recent 10-Q or 10-K filings for the company's current cash balance and burn rate to contextualize the liquidity impact of this raise.